1 (Image 1)
Sunitinib Malate Capsule
Product Images NDC 0093-8231
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 0093-8231). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Image 2)
1 (Image 3)
The given text shows the results of two treatments Sunitinib Malate and IFN-a on 375 subjects. Sunitinib Malate shows a median of 47.3 weeks of treatment whereas IFN-a shows a median of 22.0 weeks. The Hazard Ratio calculated is 0.42 with a 95% CI (0.32, 0.54). Based on the Progression-Free Survival Probability, Sunitinib Malate shows better results. However, it is important to note that there might have been a significant difference in the treatment methods or processes, which can affect the validity of direct comparison between these treatments.*
1 (Image 4)
This text provides data on disease-free survival probability over 6.8 years for a group of 309 subjects treated with Sunitinib malate and a group of 306 subjects treated with a placebo. The hazard ratio between the two groups is 0.76 with a 95% confidence interval of 0.59 to 0.98 and a p-value of 0.03. A graph shows the probability of disease-free survival over time.*
1 (Image 5)
This text presents data on the Progression-Free Survival Probability (%) for individuals that received Sunitinib Malate compared to those that received a placebo. The hazard ratio was 0.427, indicating that individuals who received Sunitinib Malate had a significantly lower risk of progression than those who received placebo. The median progression-free survival time for Sunitinib Malate was 10.2 months, whereas the median time for placebo was 5.4 months. The 95% confidence interval for the hazard ratio was 0.271-0.673, and the p-value was 0.0000146. The text also includes a figure showing the percentage of subjects remaining progression-free over time for each treatment group.*
1 (Image 6)
This is a medication label for Sunitinib Malate Vsl with a dosage of 12.5mg per capsule. The capsules need to be stored at a temperature range of 68-77°F, and should be kept out of reach of children. The manufacturer of the medication is B. The label includes the NDC number, dosage information, and manufacturing details.*
1 (Image 7)
1 (Image 8)
1 (Image 9)
This is a medication called Sunitinib Malate, which comes in capsule form. The usual dosage for this medication can be found in the accompanying prescribing information. It should be stored between 20°C to 25°C and dispensed in a tightly sealed container, and kept out of reach of children. The manufacturer is Teva Pharmaceuticals USA, Inc. The text includes a prescription number, lot number, and other important information for pharmacists.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
